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Abstract
Bone healing involves a variety of different cell types and biological processes. Although
certain key molecules have been identified, the molecular interactions of the healing
progress are not completely understood. Moreover, a clinical routine for predicting the
quality of bone healing after a fracture in an early phase is missing. This is mainly due to a
lack of techniques to comprehensively screen for cytokines, growth factors and metabo-
lites at their local site of action. Since all soluble molecules of interest are present in the
fracture hematoma, its in-depth assessment could reveal potential markers for the moni-
toring of bone healing. Here, we describe an approach for sampling and quantification of
cytokines and metabolites by using microdialysis, combined with solid phase extractions
of proteins from wound fluids. By using a control group with an isolated soft tissue wound,
we could reveal several bone defect-specific molecular features. In bone defect dialy-
sates the neutrophil chemoattractants CXCL1, CXCL2 and CXCL3 were quantified with
either a higher or earlier response compared to dialysate from soft tissue wound. More-
over, by analyzing downstream adaptions of the cells on protein level and focusing on
early immune response, several proteins involved in the immune cell migration and activ-
ity could be identified to be specific for the bone defect group, e.g. immune modulators,
proteases and their corresponding inhibitors. Additionally, the metabolite screening
revealed different profiles between the bone defect group and the control group. In
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summary, we identified potential biomarkers to indicate imbalanced healing progress on
all levels of analysis.
Introduction
Bone exhibits the remarkable ability for self-repair without scarring [1]. The healing process
consists of three overlapping stages: (i) inflammation, (ii) repair, and (iii) remodeling. Each
stage is orchestrated by a specific set of biological events [2]. Thereby, several key cells like oste-
oblasts, osteoclasts and osteocytes as well as immune cells interact with each other and their
microenvironment. Pro-osteogenic and angiogenic factors but also inflammatory chemokines
and cytokines, are secreted and interact with the extracellular matrix (ECM) and several cell
types resulting in optimal fracture repair and restoration of the skeletal functions [3–5]. A per-
sistent inflammatory response and a failed transition to the repair stage can disrupt the bone
healing process and thus result in delayed, impaired or completely absent bone healing after
acute fractures. Thus, the inflammatory stage which is simultaneously activated with the for-
mation of the fracture hematoma may be crucial for consolidation [6, 7]. During the initial
stage of inflammation activated platelets and degranulating neutrophils infiltrate the fracture
site and release inflammatory cytokines [8]. Although the function of the cells involved in this
process is well described, the knowledge about the molecular mechanisms after wounding is
still scarce. This includes the temporal and spatial interplay of individual immune mediators as
well as the downstream response of the cells in the wound area, in terms of protein expression
and metabolic adaptions. To promote this understanding, it is relevant to identify and quantify
chemokines and cytokines, other proteins like ECM components, proteases and protease inhib-
itors as well as various metabolites directly at their site of action.
Since the wound fluid adjacent to the fracture site contains all the soluble factors released
into the microenvironment of the fracture hematoma, its assessment provides remarkable
insights into the wound milieu [8, 9]. Microdialysis has become an established method to sam-
ple wound fluid from a variety of tissues, including skin, brain and liver [10–12]. We recently
established microdialysis in a critical-size bone defect and demonstrate that cytokines can be
sampled and quantified by enzyme-linked immunosorbent assays (ELISA) continuously over
24 hours [13]. The sampling is based on the diffusion of molecules across a semi-permeable
membrane driven by a concentration gradient. However, due to the high biological activity of
most cytokines, their concentration in body fluids is rather low [14]. Nevertheless, the direct
analysis of the chemokines and cytokines is beneficial because genomic approaches do not dis-
play the functional microenvironment at the site of injury. Measuring mRNA or DNA expres-
sion may indicate a cellular upregulation of the relevant chemokines and cytokines but
transcriptional regulations or posttranslational modifications as well as protein degradation
can modulate the protein abundance [15]. A major benefit of microdialysis is the fact that it is
minimally invasive and allows continued sampling during the wound healing process and thus
a time-dependent analysis of metabolites and cytokines of the same individuals.
Mass spectrometry is an ideal tool for the identification and quantification of proteins and
metabolites from body fluids in an untargeted approach and the combination of microdialysis
and proteomics has been widely used to identify and quantify proteins and peptides simulta-
neously [16–18]. However, the sampling of proteins by using microdialysis is highly challeng-
ing, because the recovery depends to a great extent on the properties of the proteins including
molecular weight, shape, charge of the molecule, binding to the membrane, and a possible
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degradation of the proteins [12]. Additionally, a high salt content, a high complexity and a low
overall concentration of proteins in the wound fluids interfere with successful comprehensive
screening. Thus, proteomic analyses were limited to the quantification of only few dozen to
about 150 proteins regardless of the sampling technique [17, 19, 20]. Recently, we established a
sampling approach that allows the identification of more than 500 proteins by using a solid
phase extraction of proteins adsorbed to the microdialysis catheter. Moreover, this approach
can be combined with the classical continuous sampling of cytokines and of metabolites [21].
In order to identify bone-specific markers we applied microdialysis in combination with
proteomics and metabolomics in two different wound scenarios in a rat bone defect (BD) and
soft tissue wound (STW). Dialysates were used for analysis of selected chemokines and cyto-
kines by ELISA to obtain time-resolved data during the first 24 hours after injury.
Materials and Methods
Animal Surgery
The study was approved by the Agency for the Inspection of Veterinary and Food Materials of
the Government of Saxony (permission no. 24–9168.11-1/2013-31). All animals were housed
according to the European guidelines for the care and use of laboratory animals. Forty-four
male Wistar rats with an average body weight of 350 g were obtained from Janvier (Le Genest
Saint Isle, France) and held in the animal care unit for at least 7 days before the experiments.
The rats were anesthetized with a solution of ketamine (100 mg/kg body weight) and xyla-
zine (10 mg/kg body weight) and kept under anesthesia up to 12 hours (administration of keta-
mine/xylazine through a permanent intraperitoneal catheter every 90–120 min). After shaving
and disinfection of the right hind leg a 3 cm longitudinal incision was made and the femur was
surgically exposed by dissecting the thigh muscle. A five-hole plate (Stryker, Hamburg, Ger-
many) was fixed with 4 screws (1.5 x 6 mm) on the femur. In twenty four rats a 5 mm bone
defect was created using a wire saw (group: bone defect, BD). In twenty rats the bone was not
injured and only a soft tissue wound was created down to the femur (control group: soft tissue
wound, STW). The microdialysis catheter (CMA/20, CMAMicrodialysis AB, Solna, Sweden,
cut-off 100 kDa) was inserted either into the soft tissue defect near the bone or into the bone
defect. The muscle was closed with absorbable sutures and the skin was closed with suture
clips. The remaining animals were allowed to wake up and move freely after closure of the
muscle and skin. After 12 hours these animals were anesthetized again and microdialysis cathe-
ter was inserted after opening the wound area 1 cm. The rats were covered with thin sheets to
avoid hypothermia. Additionally, a mixture of 0.25 mL 0.9% NaCl solution and 0.25 mL 10%
glucose was administered every 120 min through the permanent catheter to avoid hypoglyce-
mia and dehydration. The rats were sacrificed under anesthesia at the end of the experiment by
CO2 inhalation.
Microdialysis
Before insertion, the microdialysis catheter was primed with an initial flush (5 μL/min) for 15
min. The membrane was perfused with perfusion fluid (PER, 147 mmol/L NaCl, 4 mmol/L
KCl, 2.3 mmol/L CaCl2, 1% bovine serum albumin) at a flow rate of 2 μL/min using a CMA402
microdialysis pump (CMAMicrodialysis AB, Solna, Sweden). The samples were collected over
12 h in 3 h intervals on ice. To avoid protein degradation PMSF (phenylmethylsulfonylfluoride,
final concentration 1 mmol/L) was added to each collection tube. The dialysates were aliquoted
and immediately stored at -20°C. The catheter was explanted at the end of the experiment and
stored at -20°C.
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Histology
At the end of the experiment the fracture hematoma was explanted, fixed with 4% formalde-
hyde, embedded in paraffin, and cut into 2 μm-sections for Pappenheim´s staining. For quanti-
fication mononucleated and multinucleated cells were counted in 10 randomly distributed
squares per section on three subsequent slices per fracture hematoma.
ELISA
The concentration of 15 cytokines and growth factors were analyzed with commercially avail-
able ELISA kits (Table 1). The ELISA assays were performed according the manufacturer’s
instructions. Mean and standard deviation were calculated when at least 3 values were above
the detection limit of the relevant ELISA.
Sample Preparation and Acquisition for Proteomics
The sample preparation and acquisition was conducted as previously described [21]. Briefly,
protein adsorbates (n = 4 for each wound scenario explanted after 12 h) were eluted from the
catheter membrane with Laemmli buffer for 5 min at 95°C. The eluted proteins were separated
by 1D-SDS-PAGE. The samples were sliced to 8 gel fractions each and an in-gel proteolytic
cleavage was conducted using trypsin. 52 ng of the Proteomics Dynamic Range Standard
(UPS2, Sigma Aldrich, Seelze, Germany) was spiked into each fraction. For control experi-
ments, proteins from microdialysates were purified using Vivacon spin tubes (10 kDa MWCO,
Sartorius, Göttingen, Germany). Proteins were reconstituted in Laemmli buffer, separated by a
1D-SDS-PAGE and treated as described above but without spiking-in the UPS2.
LC-MS/MS analyses were performed with a nano-HPLC system (nanoAcquity, Waters,
Milford, MA, USA) online coupled to a LTQ Orbitrap XL ETD mass spectrometer (Thermo
Fisher Scientific, San Jose, CA, USA). Peptide separation was achieved by RP-LC using a 90
min non-linear gradient (2–40% acetonitrile containing 0.1% formic acid). After MS full scan
(positive mode,m/z 350 to 1,600, R = 60,000) MS/MS acquisitions of the six most abundant
ions were automatically triggered when exceeding an intensity threshold of 3,000 counts. A
dynamic exclusion was set for 120 sec limiting the list to a maximum of 500 entries. Fragmen-
tation was conducted with the linear ion trap by collision induced fragmentation (CID, isola-
tion window of 4 amu, normalized collision energy 35, activation time 30 ms, activation Q
0.25).
Table 1. List of used enzyme-linked immunosorbent assay (ELISA) kits. All kits were purchased as indicated and used according to the manufacture’s
guide.
Cytokine/growth factor ELISA kit Company Detection limit
IL-6 Rat Il-6 Quantikine ELISA kit R&D Systems, Wiesbaden, Germany 10 pg/mL
TGF-ß1 Mouse/Rat/Porcine/Canine TGF-beta1 Quantikine ELISA kit R&D Systems, Wiesbaden, Germany 1.7 pg/mL
CXCL1 (CINC-1) Rat CXCL1/CINC-1 Quantikine ELISA kit R&D Systems, Wiesbaden, Germany 1.1 pg/mL
CXCL2 (MIP-2) MIP-2 ELISA kit Life Technologies, Darmstadt, Germany 1 pg/mL
CXCL3 Chemokine (CXC motif) Ligand 3 (CXCL3) ELISA kit Cloud-Clone Corp., Houston, USA 5.5 pg/mL
CXCL4 (PF4) Platelet factor 4 (PF4) ELISA kit Cloud-Clone Corp., Houston, USA 128 pg/mL
CXCL7 CXCL7 Rat ELISA kit Abcam, Cambridge, UK 80 pg/mL
SDF-1 (CXCL12) Chemokine (CXC motif) Ligand 12 (CXCL12) ELISA kit Cloud-Clone Corp., Houston, USA 0.125 ng/mL
IL-10 Rat IL-10 Quantikine ELISA kit R&D Systems, Wiesbaden, Germany 10 pg/mL
doi:10.1371/journal.pone.0159580.t001
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Protein Identification and Quantification by Mass Spectrometry
The obtained MS raw data were processed using MaxQuant (Version 1.5.2.8) [22]. With the
integrated search engine Andromeda [23] a target-decoy database search was performed. A ref-
erence set containing all annotated rat proteins (Uniprot, version 18th June 2015, 27,764
entries) in forward and reverse direction was used. Trypsin was set as endoprotease allowing
for a maximum two missed cleavages. Acetylation of the protein N-terminus and oxidation of
methionine were set as variable modifications whereas carbamidomethylation of cysteine was
set as fixed modification. A precursor mass tolerance of 25 ppm was defined for first search. At
least two peptides including one unique peptide were set as requirement for protein identifica-
tion. The false discovery rate (FDR) for peptide and protein identification was controlled to be
below 0.05. For protein quantification the MaxQuant integrated MaxLFQ algorithm for label-
free protein quantification was used [24]. If not stated otherwise MaxQuant default values were
used.
Metabolomic Profiling and Quantification by Mass Spectrometry
Reconstituted microdialysate samples from 12–24 h after injury (n = 3 for BD, n = 6 for STW,
50 μL each) were precipitated by adding 500 μL of ACN. The samples were centrifuged, evapo-
rated and reconstituted as described by Hoeke et al. [25].
LC-MS analysis was conducted on a Thermo Fischer Orbitrap Velos system using ESI posi-
tive ionization and UHPLC separation as described previously [25]. For details see Supporting
Information. In addition, full scan acquisition (m/z 100–800, resolution = 30,000) using identi-
cal MS parameters was used for quantitative analysis. Data analysis was performed by XCMS
online [26] using “HPLC / Orb (136)” parameters. Detailed information on the XCMS settings
were described in S1 Text.
Data obtained by XCMS analysis was confirmed by targeted LC-MS analysis using Abso-
luteIDQ p150 kit (BIOCRATES Life Sciences AG, Innsbruck, Austria) to quantify 163 metabo-
lites as described elsewhere [21]. All experiments were carried out on an Agilent 1100 series
binary HPLC system (Agilent Technologies, Waldbronn, Germany) coupled with an 4000
QTRAP™ linear ion trap mass spectrometer (AB Sciex, Concord, Canada) equipped with a Tur-
boIon spray source. The FIA-analysis was performed with MS running solvent at ambient tem-
perature. Quantification was achieved by multiple reaction monitoring (MRM) detection in
combination with the use of stable isotope-labeled and other internal standards. Data evalua-
tion for quantification of metabolite concentrations was performed with the MetIQ™ software
package.
Bioinformatics
Cell number was given as mean ± standard deviation (SD) and statistical significance was
tested by Student t-test. The level of significance was set at p< 0.05.
ELISA data were statistically analyzed with the Kruskal-Wallis test. The Mann-Whitney test
was used to detect post hoc statistical significance between selected groups. Statistical signifi-
cance was set at p< 0.05.
All quantitative values for proteins gained from mass spectrometry were log10-transformed
and median normalized, first between all corresponding fractions of each sample and after-
wards between all samples. Proteins with quantitative values in at least three replicates of one
condition and in none of the other were considered to be unique for the corresponding condi-
tion. Proteins with quantitative values in at least three replicates of both conditions were con-
sidered as quantified. To be treated as significantly higher abundant the log10-ratio in
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comparison of both conditions must be> 0.3 with a p-value of less than 0.05 (two-tailed,
unpaired student’s t-test).
Protein clustering was based on Gene ontology (GO) assignments (GO:BP_FAT, GO:
CC_FAT and GO:MF_FAT) using DAVID Bioinformatics Resources 6.7 [27] and refined by
manual literature research. For an enrichment analysis a list of known extracellular rat proteins
(evidences gained by mass spectrometry) provided by the ExoCarta database [28] (release date
29th July 2015) was used as background list. A principle component analysis (PCA) was con-
ducted by using R and the package ggbiplot [29, 30]. Additionally, the quantitative protein data
were analyzed through the use of QIAGEN’s Ingenuity1 Pathway Analysis (IPA1, QIAGEN
Redwood City, www.qiagen.com/ingenuity). The log10-ratios and p-values of all quantified
proteins were included. Unique proteins were assigned to a log10-ratio of 1 or -1, respectively,
and p = 0.01.
Results and Discussion
Bone repair is a highly complex process requiring the synchronization of multiple biological
pathways to restore tissue integrity. Activation of these pathways gives rise to unique wound
and fracture microenvironment that consists of cells and ECM including a complex milieu of
enzymes, growth factors, and cytokines that control the tissue repair response. Thus, the real
therapeutic challenge in enhancing bone healing is to provide an ideal microenvironment for
optimal cell migration and proliferation. Nevertheless, the whole process in its complexity is
still poorly understood. Even though the significance of single proteins is determined, for a
thorough understanding of the whole process it is relevant to identify and quantify the involved
molecules at their site of action. It is well known that the initial inflammatory stage is essential
for later consolidation [31–33]. Hence, the aim of this study was the identification and quantifi-
cation of chemokines, cytokines and further proteins involved in the early stage of bone healing
as well as metabolites that could provide further insight into the metabolic adaptions following
a fracture.
Because the concentration of the cytokines in plasma does not represent the concentration
in the injured tissue, quantification at the wound site is highly desirable [34, 35]. Microdialysis
is an ideal sampling technique as it provides the capability to monitor these proteins in real
time in their surrounding milieu. However, chemokines and cytokines are small molecules
present in low concentration. In addition, the BSA added to the perfusate to increase the recov-
ery of proteins cover the signals from the chemokines and cytokines. Taken together, this leads
to an underrepresented identification and quantification of those proteins in a nanoLC-MS/
MS approach [21]. Hence, ELISAs were used to quantify the cytokines in the dialysate because
of their acceptable specificity, sensitivity, and the ease of performance.
Even though microdialysis is a minimally invasive technique, there is also evidence that the
insertion of the catheter into the tissue can change the interstitial concentration of cytokines
[36]. But since BD as well as STW are dramatic injuries the effect of implantation of the cathe-
ter in the present experiment is expected to be negligible compared to the inflammation and
thus the cytokine response caused by the injuries.
Clinical Findings
Forty three rats survived the surgery without any complications. One animal died due to severe
anemia during the surgery. Three animals died during the experiment without any identifiable
reason. The dialysates of eleven rats with BD and those of 9 rats with STW each sampled at
0–12 h and 12–24 h could be used for ELISA analysis.
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Determination of Cytokines and Growth Factors with ELISA
In total the abundance of 15 cytokines and growth factors were investigated in the dialysate
from BD and STW. Under the experimental conditions six cytokines and growth factors were
not detectable (BMP-2, VEGF, PDGF-BB, IL-1α, IL-1β, and TNF-α) which might be due to
several reasons. First, the recovery of proteins depends reciprocally on their molecular weight
[37]. Although we used a cut-off of 100 kDa the larger cytokines VEGF (MW appr. 40 kDa) or
PDGF-BB (MW appr. 30 kDa) seem to be unable to cross the membrane with sufficient recov-
ery which is in line with the observation that an acceptable recovery will only be attained if the
molecular weight of the proteins is lower than approximately one-fourth of the membrane cut-
off [38]. However, we used this cut-off to avoid the recovery of serum proteins and to avoid an
influx of perfusion fluid into the wound area which we have seen using catheter with larger
pore size. Second, the recovery is also controlled by the concentration of the protein. A higher
concentration of the protein means a higher concentration gradient driving the transfer over
the membrane [39]. Third, since it is well known that most cytokines are usually found in low
picomolar concentrations [14] we cannot exclude that the concentration of these investigated
proteins in the wound fluid was already below the detection limit. Forth, the composition of
the perfusion fluid, the flow rate and the area of the membrane are further criteria influencing
the recovery of proteins [40]. The optimization of the perfusion fluid composition and the flow
rate we described previously [13]. But we cannot exclude that other flow rate or buffer compo-
sition could result in detectable protein concentrations. The length of the used membrane was
4 mm, because the diameter of the rat femur is about 3–4 mm. The sampling of proteins from
BD could thus be limited to the area of the BD because the catheter tip does not stick out into
the soft tissue. Despite these challenges and limitations, microdialysis can be used to receive
both time-dependent qualitative and quantitative data from the site of injury which cannot be
achieved by other discontinuous methods.
For nine markers assessed, concentration profiles could be obtained (Fig 1). IL-6, CXCL1,
CXCL2, and CXCL3 showed an increase in concentration after surgery and a re-equilibration
to baseline after 24 h. The concentrations of CXCL4 and CXCL7 decreased immediately after
surgery, suggesting a release of the proteins from activated cells. SDF-1, TGF-β1, and IL-10 did
not show any changes in concentration over the first 24 h after surgery.
The key function of IL-6 is mediation of the acute phase response. After release at the site of
injury IL-6 moves to the liver through the bloodstream and induces the synthesis of acute
phase proteins such as C-reactive protein, fibrinogen, serum amyloid A, haptoglobin, and
α1-antichymotrypsin (SerpinA3) in hepatocytes [41]. In the present series, IL-6 concentration
in the dialysate peaked earlier in the STW than in the BD. The highest concentration of IL-6 in
BD was detected 12–15 h after surgery. In contrast, for STW the maximum was reached at 6–9
h. The early increase after the injury underlines the role of IL-6 in the acute phase response.
With the Kruskal-Wallis test the differences in the time response of the IL-6 concentrations in
STW was statistically significant different (p = 0.006). In the intervals 6–9 h and 9–12 h the
absolute IL-6 concentration was significantly higher in STW than in BD (6–9 h: p = 0.047;
9–12 h: p = 0.007). A similar time response was found in UVB-irradiated skin. IL-6 increased
rapidly after 8–16 h and declined to baseline after 24 h [10].
CXCL1, CXCL2, and CXCL3 are all potent chemoattractants for neutrophils and are con-
sidered to play key role in neutrophil infiltration in inflammatory diseases [42]. All three
CXCLs have a similar ability to induce chemotaxis for neutrophils in vitro and in vivo [43, 44].
However, the contribution of each CXCL to neutrophil infiltration in vivo seems to depend on
the amount of each CXCL at the site of inflammation [45]. In addition, in rat the proportion of
each CXCL at the site of inflammation depends on the type of inflammation [42].
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Fig 1. Concentration of chemokines and cytokines in the dialysate from bone defect (BD) and soft
tissue wound (STW) 0–24 h after injury. Samples were analyzed by ELISA. Values are mean ± SD. IL-6,
interleukin-6; CXCL2, chemokine (C-X-C motif) ligand 2; CXCL7, chemokine (C-X-C motif) ligand 7; CXCL3,
chemokine (C-X-C motif) ligand 3; CXCL1, chemokine (C-X-C motif) ligand 1; CXCL4, chemokine (C-X-C
motif) ligand 4; IL-10, inteleukin-10; TGF-β1, transforming growth factor-β1; SDF-1, stromal-cell derived factor-
1. * p < 0.05, ** p < 0.01, *** p < 0.001.
doi:10.1371/journal.pone.0159580.g001
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CXCL1 expression has been demonstrated for platelets but also endothelial cells, neutro-
phils, monocytes, and macrophages [46–48]. In BD the highest CXCL1 concentration was
detected 6–9 h after surgery. In STW the highest CXCL1 concentration was seen 3–6 h after
surgery. For both defect scenarios the time response showed significant differences (BD:
p = 0.007; STW: p = 0.004) resulting in p-values p< 0.01 determined by a post hoc test. In the
intervals 15–18 h and 18–21 h the differences between BD and STW were statistically signifi-
cant (15–18 h: p = 0.005; 18–21 h: p = 0.025). CXCL1 is constitutively expressed by endothelial
cells, megakaryocytes in the bone marrow, and to a lesser extent by osteoblasts [49, 50]. This
might explain the higher CXCL1 concentration in BD compared to STW where the bone and
thus the bone marrow were not injured.
The macrophage inflammatory protein 2 alpha (CXCL2) is not stored in platelets but
expressed, among other cells, by macrophages and monocytes [51]. In contrast to the IL-6 con-
centration, CXCL2 in the dialysate peaked earlier in BD than in STW. The highest CXCL2 con-
centration in BD was detected 6–9 h after surgery while the maximum level in STW was
detected 12–15 h after surgery. However, 12 h after surgery no CXCL2 was detectable in BD.
The post hoc test revealed significant differences between 0–3 h and 3–6 h (p< 0.001), 6–9 h
(p< 0.001) and 9–12 h (p = 0.002). The total CXCL2 concentration was higher in STW than in
BD.
The CXCL3 concentration was highest 6–9 h after surgery in BD as well as in STW. In BD
CXCL3 was not detectable anymore after 12 h. Nevertheless, the time response was statistically
significant different in BD (p = 0.013) and STW (p< 0.001) and resulted in p-values from post
hoc tests below p< 0.01.
For all three CXCL types we found a similar time response. The concentration increased
immediately after injury, peaked early and then decreased after 12–15 h. For CXCL1 and
CXCL2 the inflammatory response was comparable to that in a rat burn model. In the latter,
serum CXCL1 increased rapidly after 3 h and then decreased slowly while CXCL2 showed a
rapid increase immediately after the injury with a peak at 6 h and then a dramatic decrease
between 12 h and 24 h [52] similar to the missing CXCL2 in BD after 12 h in the current
experiment.
Platelet factor 4 (CXCL4) and pro-platelet basic protein (CXCL7) are abundant chemokines
in the α-granules of platelets that are released during platelet activation [53]. This is in accor-
dance with the concentration profile determined for CXCL4 and CXCL7 in the present study.
In BD and STW the CXCL4 concentration decreased after surgery and reached steady-state
level 9–12 h after surgery. The difference in time response was not statistically significant dif-
ferent (BD: p = 0.099; STW: p = 0.981).
For CXCL7 the concentration decreased from 27.3 ng/mL (SD 26.8 ng/mL) at 0–3 h to 0.8
ng/mL (SD 0.68 ng/mL) at 12–15 h and remained at low level for the rest of the sampling inter-
vals in BD. In STW the steady state level was reached with the 6–9 h interval. However, the
time response for STW is statistically significant different (p = 0.02).
A third time-dependent concentration profile was found for IL-10, TGF-ß1 and SDF-1. For
these cytokines, the concentration in the samples did not change over time. IL-10 is an anti-
inflammatory cytokine and thus it will be upregulated at the end of the inflammatory stage. On
the other hand, there is evidence that the recovery of IL-10 is low because of a larger hydrody-
namic radius compared to other cytokines [40, 54].
TGF-β1 is important in all wound healing stages. In the inflammatory stage it is released by
platelets and facilitates the recruitment of additional inflammatory cells and MSCs [3, 55].
After that TGF-β1 is being expressed by other cells over 21 days during fracture healing [3]. In
STW TGF-β1 was only detectable until 12–15 h after surgery. Until then the concentration
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slightly increased from 9.2 pg/mL (SD 12.9 pg/mL) to 21.7 pg/mL (SD 17.6 pg/mL). For BD
the TGF-β1 concentration ranged from 3 to 17 pg/mL over 24 h.
The concentration of SDF-1 in the BD samples remained constant over the whole 24 h. In
STW samples the SDF-1 concentration increased after the first interval and post hoc test iden-
tified a statistically significant increase from 0–3 h to 6–9 h (p = 0.017). SDF-1 recruits MSCs
during endochondral bone repair. An increase of the SDF-1 mRNA was not observed before
day 2 in a mouse segmental bone graft model [56]. Thus, the constant local protein level over
the first 24 h after creation of a bone defect may indicate an early steady state before systemic
upregulation.
The ELISA results show that microdialysis is a suitable method to determine the concentra-
tion profiles of various proteins associated with the inflammatory stage of the healing process.
In addition, we could show differences between BD and STW. This is an important fact because
it is now possible to identify dysregulated proteins in delayed wound and fracture healing. Sec-
ond, influencing the expression or the release of these proteins could result in an improved
healing process.
The number of polymorphonuclear cells in the fracture hematoma from BD was signifi-
cantly lower after 12 h compared to 24 h indicating the beginning of the inflammatory stage
(Fig 2A). After 12 h we could mostly detect neutrophil granulocytes and some monocytes. In
the fracture hematoma 24 h after surgery increased number of neutrophil granulocytes but also
eosinophil and basophile granulocytes were seen (Fig 2B and 2C). The increase in polymorpho-
nuclear cells corresponds to the time line of cellular migration during healing. After coagula-
tion neutrophils are the first cells arriving at the wound site peaking after 24–48 h. They are
responsible for phagocytosis and wound debridement and thus they decrease the rate of infec-
tions [57, 58]. Neutrophils are important cells because they also produce and express chemo-
kines which chemoattract further immune cells and as a result the healing process is going on.
Fig 2. Analysis of the fracture hematoma from BD 12 h and 24 h after surgery. (A) Number of
mononucleated and multinucleated cells in the fracture hematoma. Cells were counted in 10 randomly
distributed squares per section on three subsequent slices per fracture hematoma. (B) Pappenheim staining
of fracture hematoma 12 hours after surgery. (C) Pappenheim staining of a fracture hematoma 24 h after
surgery. Magnification 100x. *, neutrophil granulocyte; #, monocyte; black arrow, basophil granulocyte; white
arrow, eosinophil granulocyte.
doi:10.1371/journal.pone.0159580.g002
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We could only analyze the fracture hematoma from BD because no hematoma was formed in a
STW.
Wound Fluid Proteomics
The combination of microdialysis with proteomics provides additional information about the
composition of the fracture hematoma and could be used in order to identify potential bio-
markers of bone healing. In the present experiment, the total amount of protein recovered
from BD or STW by microdialysis was too low for HPLC-MS/MS analysis. We identified only
28 proteins, most of them ubiquitously produced in cells (S1 Table). We therefore used the pro-
teins adsorbed to the tip of the microdialysis catheter membrane for proteomic analysis. This
allows for effective and reproducible sampling as has been shown recently [21]. By using this
approach an overall number of 513 proteins could be identified in a comparative analysis of
both defect scenarios. Among those 273 proteins could be reliably quantified (S2 Table).
To identify significant alterations in the protein composition of fluids from different wound
scenarios, two different approaches were pursued: (i) identification of unique proteins for a
certain wound scenario and (ii) a determination of significant higher abundance of proteins for
a certain wound scenario. To be considered as unique, a protein must be quantified in at least
three of four replicates of one wound scenario but in none of the other. To be considered as sig-
nificantly higher abundant, the Log10-ratio of the protein abundance in both defect scenarios
must exceed 0.3 (= 1-fold increase) with a p-value of p< 0.05 (student’s t-test). The 19 quanti-
fied proteins of the spiked-in Proteomics Dynamic Range Standard served as control (Fig 3A).
None of the spiked-in standard proteins was identified as significantly regulated, indicating a
successful quantification and normalization procedure. By applying both described strategies
to all 273 reliably quantified proteins, 107 of them could be assigned to a certain wound sce-
nario (Fig 3B). The number of specific proteins for the bone defect group (BD, 30 unique, 50
by higher abundance) was notably higher than the number for the soft tissue wound group
(STW, 2 unique, 25 by higher abundance). This difference appears plausible because the BD
scenario has all features of the STW but with an additional fracture of the femur.
To confirm a specific protein profile of the sampled wound fluids for a given defect scenario
a principle component analysis (PCA) of all quantified proteins was conducted (Fig 4). The
two defect groups could be separated by this analysis.
In summary, by (i) identifying unique proteins for both defect scenarios, (ii) showing a sig-
nificant higher abundance of several proteins depending on certain wound scenarios and (iii)
by the clear separation of both defect types in the PCA, defect-specific protein profiles can be
considered.
Identification of Early Wound or Fracture Healing Markers
To gain deeper insight into the biological potential of the wound fluids all quantified proteins
were assigned to functional clusters based on GO-term assignment and manual literature
research. An enrichment analysis of all quantified proteins revealed, among others, an increased
presence of proteins being involved in proteinase inhibition (enrichment score = 3.8), wound-
ing and inflammatory response (3.29), apoptosis (2.79), tissue regeneration (2.46), blood coagu-
lation (2.43) and lymphocyte chemotaxis and activation (2.06) (S3 Table). Moreover, a
signaling pathway analysis revealed several enriched and activity-altered processes (S4 Table).
A selection of higher hierarchical signaling pathways with a focus on cellular adhesion and
migration (Fig 5A) and immune response (Fig 5B) is shown. Several pathways are predicted to
be in a higher activity state in the bone defect group. This could indicate an increased invasion
of immune cells to the wound area after a femur fracture compared to the soft tissue wound.
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Fig 3. Comparative analysis of protein adsorbates sampled from bone defect (BD) and soft tissue wound (STW) at 12 h after
injury. n = 4 for each defect scenario. (A) Volcano plot of proteins quantified in both defect scenarios: Data points represent the
Log10-transformed ratios of the mean quantitative values gained from BD or STW and the -Log10-transformed p-value of the
comparative analysis. (B) Proportions of unique and specific proteins for a certain wound scenario among all quantified proteins. The
numbers in brackets represent the number of proteins assigned to the corresponding groups.
doi:10.1371/journal.pone.0159580.g003
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The acute phase response signaling is one of only two pathways with a decreased activity. This
confirms the finding of an earlier IL-6 response in the soft tissue wound.
Since an impaired wound healing is believed to be based on an improper inflammatory
response, we manually clustered all quantified proteins to early wound healing mechanisms
including ECM proteins, immune modulators, proteases and protease inhibitors as described
before [19] (S5 Table). Tables 2–5 lists the top 15 most abundant proteins including all unique
or specific proteins for a certain wound scenario, assigned to those clusters.
Different Abundance of ECM Proteins in Wound Fluids
Proteins forming insoluble fibers are essential for primary wound closure. Moreover, they pro-
vide a provisional ECM for the migration and adhesion of immune cells and re-epithelization.
Overall, nine proteins could be assigned to the ECM protein cluster (Table 2). With fibrinogen
alpha and gamma chain (FGA, FGG) and fibronectin (FN1) two were specific by higher abun-
dance for the STW group. The mature fibrin and FN1 were shown to be involved in forming a
provisional ECM [59, 60]. The earlier formation of a provisional ECM is in line with the find-
ing of an earlier response of the acute phase mediator IL-6 in the STW group compared to the
BD group. However, alpha 2 HS-glycoprotein (AHSG) was also identified specific by higher
abundance for the STW group. This protein was shown to be negatively correlated to the acute
wound healing phase [61]. Galectin-3 (LGALS3), olfactomedin 4 (OLFM4), and annexin A2
Fig 4. Principle component analysis (PCA). n = 4 for each defect scenario. PCA based on protein quantitative values gained from each replicate of
bone defect (BD) and soft tissue wound (STW) at 12 h after injury.
doi:10.1371/journal.pone.0159580.g004
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(ANXA2) were specific for BD. LGALS3 has been shown to be involved in the acute inflamma-
tory response including chemoattraction of monocytes and macrophages, as well as neutrophil
activation and adhesion [62, 63]. OLFM4 has been found in granules of neutrophils [64, 65]
and appears to be an important regulator of the innate immunity against bacterial infections
[66]. On the other hand, OLFM4 was reported in higher abundance in chronic non-healing
wounds [19]. ANXA2 is expressed in endothelial cells, macrophages and mononuclear cells
[67]. Recent studies suggest that secreted ANXA2 can activate macrophages to secret IL-1, IL-
6, and TNF-α, and can recruit and activate immune cells to the site of infection [68, 69].
Fig 5. Signaling pathway analysis. n = 4 for each defect scenario. Regulation of selected pathways focusing on cellular migration (A) and immune
response (B) revealed by Ingenuity Pathway Analysis (IPA). The quantitative values of all proteins were used. Z-score reflects the pathway activity with
orange indicating an increased activity in the bone defect group and blue a decreased activity, respectively.
doi:10.1371/journal.pone.0159580.g005
Table 2. Identified proteins clustered to extracellular matrix proteins. Identified proteins from proteomic
analysis at 12 h after injury. Gene symbols and protein names correspond to Uniprot Knowledgebase. Quanti-
tative values are given as Log10-transformed fold changes BD/STW. Significances are indicated as asterisks
with * p-value < 0.05, ** p-value < 0.01 and *** p-value < 0.001. n = 4 for each defect scenario.
Gene symbole Protein name Log10 BD/STW
OLFM4 Olfactomedin 4 unique for BD
LGALS3 Galectin-3 unique for BD
ANXA2 Annexin A2 0.79 *
FN1 Fibronectin -0.42 ***
VTN Vitronectin -0.44
FGA Fibrinogen alpha chain -0.49 **
FGB Fibrinogen beta chain -0.38
FGG Fibrinogen gamma chain -0.49 *
AHSG Alpha-2-HS-glycoprotein -0.50 *
doi:10.1371/journal.pone.0159580.t002
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Different Abundance of Immune Modulators in Wound Fluids
The balance of the immune response has a critical role in influencing the outcome of wound
and fracture healing. Both, an inadequate primary defense against pathogens invading the
wound and an unregulated activation of the immune system overwhelming the protective
capacity of the tissue could lead to a non-healing wound or fracture nonunion. 27 proteins
with immunomodulatory capabilities were quantified in the wound fluids underlining the cru-
cial role of a proper immune response at the wound or fracture site. Ten of these proteins were
either unique or significantly higher abundant in the BD group (Table 3). This includes cyto-
solic proteins of neutrophils (neutrophilic granule protein, NGP; neutrophil cytosol factor 2,
NCF2; and neutrophil cytosol factor 4, NCF4) indicating a rapid migration of these cells into
the wound area. This is supported by a higher abundance of integrin beta (ITGB2) and protein
S100-A9 (S100-A9). Both proteins are involved in neutrophil migration towards wound sites
Table 3. Identified proteins clustered to immunemodulators. Identified proteins from proteomic analysis
at 12 h after injury. Gene symbols and protein names correspond to Uniprot Knowledgebase. Quantitative
values are given as Log10-transformed fold changes BD/STW. Significances are indicated as asterisks with
* p-value < 0.05, ** p-value < 0.01 and *** p-value < 0.001. n = 4 for each defect scenario.
Gene symbole Protein name Log10 BD/STW
NCF2 Neutrophil cytosol factor 2 unique for BD
NCF4 Neutrophil cytosol factor 4 unique for BD
CYBB Cytochrome b-245, beta polypeptide unique for BD
LCP1 Lymphocyte cytosolic protein 1 1.53 *
ITGB2 Integrin beta 1.17 *
CORO1A Coronin-1A 0.96 **
YWHAZ 14-3-3 protein zeta/delta 0.65 *
ANXA1 Annexin A1 0.49 *
NGP Neutrophilic granule protein 0.42 *
S100A9 Protein S100-A9 0.33 *
S100A8 Protein S100-A8 0.32
CRP C-reactive protein -0.22
C3 Complement C3 -0.30
CFH Complement factor H-related protein -0.68 *
PRDX2 Peroxiredoxin-2 -0.42 *
doi:10.1371/journal.pone.0159580.t003
Table 4. Identified proteins clustered to proteases. Identified proteins from proteomic analysis at 12 h
after injury. Gene symbols and protein names correspond to Uniprot Knowledgebase. Quantitative values are
given as Log10-transformed fold changes BD/STW. Significances are indicated as asterisks with * p-
value < 0.05, ** p-value < 0.01 and *** p-value < 0.001. n = 4 for each defect scenario.
Gene symbole Protein name Log10 BD/STW
PSMB10 Proteasome subunit beta type-10 unique for BD
PR3 Proteinase 3 unique for BD
MMP8 Matrix metalloproteinase 8 unique for BD
MMP9 Matrix metalloproteinase 9 0.46
NAPSA Napsin 1.03 **
Cat-G Cathepsin G 0.73 *
EL Neutrophil elastase 2 0.31
F2 Prothrombin -0.11
PLG Plasminogen -0.50 *
doi:10.1371/journal.pone.0159580.t004
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[70, 71]. Neutrophils are known to be a key player in the early innate immune response [72].
Additionally, with the lymphocyte cytosolic protein 1 (LCP1) and coronin-1A (CORO1A) two
proteins crucial for T cell activation and migration were found to be specific for the BD [73,
74]. Moreover, annexin A1 (ANXA1) was upregulated in the BD group. This protein is
involved in several pathways of the immune response but also has a crucial role for resolving
the inflammatory response in later healing stages [19, 75]. For the STW group only two pro-
teins were found to be upregulated in the immune modulating protein cluster. Of those, the
complement factor H-related protein (CFH) was shown to be a downregulator of the alterna-
tive complement activation [76].
Different Abundance of Proteases in Wound Fluids
One of the main functions of cells involved in the early immune response is the secretion of
proteases either for defense, tissue remodeling or migration purposes. However, those prote-
ases also lead to tissue damage, if the response is not resolved properly. Nine quantified pro-
teins from the sampled wound fluids could be assigned to proteases (Table 4), including five of
them being known to be secreted by neutrophils (cathepsin G, Cat-G; neutrophil elastase 2, EL;
matrix metalloproteinase 8, MMP8; matrix metalloproteinase 9, MMP9; and proteinase 3,
PR3) [77–79]. In inflammation the neutrophil proteases can activate or inactivate cytokines,
activate specific receptors, and modify the activity of chemokines [80]. Five of nine proteins
were unique or specific for the BD group, once more suggesting more intense immune
response after a fracture as compared with a pure soft tissue wound. However, to the best of
our knowledge, no influence on wound healing has yet been described for the BD-specific pro-
teasome subunit beta type-10 (PSMB10) and napsin (NAPSA). Plasminogen (PLG) was the
only protein identified in a higher abundance in the STW group. Besides its role in terminating
blood coagulation it was shown to have a role in wound healing by remodeling of the ECM
[81].
Table 5. Identified proteins clustered to protease inhibitors. Identified proteins from proteomic analysis
at 12 h after injury. Gene symbols and protein names correspond to Uniprot Knowledgebase. Quantitative
values are given as Log10-transformed fold changes BD/STW. Significances are indicated as asterisks with
* p-value < 0.05, ** p-value < 0.01 and *** p-value < 0.001. n = 4 for each defect scenario.
Gene symbole Protein name Log10 BD/STW
AGT Angiotensinogen 0.26
SERPINB1A Serine protease inhibitor EIA 1.10 *
SERPINA1 Alpha-1-antiproteinase -0.35
SERPINA3K Serine protease inhibitor A3K -0.21
SERPINA3L Serine protease inhibitor A3L -0.19
SERPINA3N Serine protease inhibitor A3N -0.05
SERPINC1 Protein Serpinc1 -0.17
SERPIND1 Heparin cofactor 2 -0.37
ITIH2 Protein Itih2 -0.51
ITIH3 Inter-alpha-trypsin inhibitor heavy chain H3 -0.20
ITIH4 Inter alpha-trypsin inhibitor, heavy chain 4 -0.54
FETUB Fetuin-B -0.39
A1I3 Alpha-1-inhibitor 3 -0.48 *
MUG1 Murinoglobulin-1 -0.52 *
AMBP Protein AMBP -0.75 *
doi:10.1371/journal.pone.0159580.t005
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Different Abundance of Protease Inhibitors in Wound Fluids
A balanced activity of immune-related proteases is, among other mechanisms, achieved by the
secretion of protease inhibitors. 20 proteins assigned to this cluster were quantified in the
wound fluids, showing the importance of proteinase inhibitors in the wound area (Table 5).
This includes nine proteins of the serine protease inhibitor protein superfamily (serpin) and
four Inter-alpha-trypsin inhibitor heavy chains. Despite its structural similarities serpins
inhibit a variety of serine proteases being involved in manifold biological processes, including
tissue remodeling [19, 82]. Inter-alpha-trypsin inhibitors are hyaluronic acid-binding proteins.
By this binding they stabilize the ECM and prevent it from degradation [83]. Four wound sce-
nario-specific proteins could be identified within this cluster. Serpin B1A –an inhibitor of the
neutrophil-released Cat-G, EL and PR3 [84]–was the only protein with a higher abundance in
the BD group. Alpha-1-inhibitor 3 (A1I3), its protein homologue murinoglobulin-1 (MUG1),
and AMBP were specific for the STW group. A significant drop of both the mRNA expression
in liver cells and the serum protein concentration of A1I3 could be shown within the first 24 h
of the acute phase [85, 86].
Different Abundance of Metabolites Elucidated by Metabolic Screening
and Validated by Targeted Quantification
Metabolic screening and subsequent targeted validation revealed significantly different regula-
tions of metabolite concentrations between BD and STW, as well as time-dependent differ-
ences. The largest differences between both wound fluids could be obtained by metabolic
screening of the sampling interval 12–15 h (Fig 6AI–6AIV). This could also be verified by tar-
geted approach indicated by highest amount of significantly regulated metabolites. Among
other mechanisms, metabolic screening revealed significant time-dependent alterations of sev-
eral amino acid pathways such as serine, tryptophan, histidine, arginine, and proline metabo-
lism in BD and STW fluids. Targeted quantification of these potential key metabolites for
wound fluid differentiation confirmed these findings with significant differences. In general
most of the monitored amino acids in BD wound fluid showed a significant higher concentra-
tion at early time-point compared to STW wound fluid (Fig 6BI and 6BII). Since the investi-
gated BD is the more severe type of inflammation this is in accordance to Yang et al. reporting
elevated levels of e.g. serine in wound dialysates in early phase of inflammation as a function of
immune response. After 24h elevated amino acid levels decreased to control level confirming
our present data [87].
Another finding in metabolic screening was a variation of the carnitine shuttle. Quantifica-
tion of 41 acylcarnitines in examined wound fluids revealed significant time-dependent differ-
ences between BD and STW samples (Fig 6BIII). Thereby it is noteworthy that concentrations
of STW and BD wound fluids showed a similar appearance resulting in highest levels at 12–15
h followed by a significant decrease of carnitine concentrations and subsequent alignment to
initial conditions. This course of acylcarnitine levels could be also explained by immune
responses as also indicated by cytokine profiling (Fig 1) [88]. A differentiation of carnitine lev-
els between STW and BD fluids was not obtained.
Furthermore, the regulation of glycerophospholipid metabolism of BD and STW fluids
obtained by metabolic screening could be verified using a targeted quantification approach.
Targeted MS analysis showed higher concentrations of glycerophospholipids in STW after 12–
15 h compared to BD (Fig 6BIV). The deeper insight using targeted quantification elucidated a
major influence of diacyl-bonded phosphatidylcholines (PC-aa) compared to acyl-alkyl (PC-
ae) or lyso-phosphatidylcholines (lyso-PC) regarding the fluid-relevant differences. Two major
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potential targets for a differentiation of STW- and BD-wound fluid are PC-aa 34 (monitored
via PC-aa 34:1, 34:2, 34:3, and 34:4) and PC-aa 36 (monitored via PC-aa 36:0, 36:1, 36:2, 36:3,
and 36:4, 36:5, and 36:6) two integral components of cell membranes which showed significant
higher levels after 12–15 h in STW compared to BD wound fluid.
Fig 6. Metabolomic results in the dialysate from bone defect (BD) and soft tissue wound (STW) 12–24 h
after injury. (A) PCA comparisons of BD vs. STW after 12-15h (I) and 21-24h (II) as well as monitoring of STW (III)
and BD after 12-15h vs. 15-18h (IV). n = 6 for soft tissue wound and n = 3 for bone defect. (B) Absolute
concentration of serine in STW and BD wound fluids (I). Summarized concentrations of all monitored amino acids,
acylcarnitines, and phosphatidylcholines-aa are shown in II-IV. Bar charts are depicted as mean + SD, * indicates
a p-value < 0.05. n = 6 for soft tissue wound and n = 2 for bone defect.
doi:10.1371/journal.pone.0159580.g006
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Conclusion and Outlook: Potentials of Combined Sampling of
Wound Fluids
In this study we established a combined sampling by a minimally invasive technique with
screening of two basic wound scenarios (bone defect and soft tissue wound) within the first 24
h after the injury. We were able to clearly differentiate between both wound scenarios and iden-
tify BD-specific features at all three levels of analysis, i.e. bone specific cytokine responses and
distinct protein and metabolite profiles. Moreover, this differentiation is based on the capabil-
ity to quantify cytokines, proteins and metabolites that can serve as a hallmark for a physiologic
or dysregulated wound or fracture healing. The response of the acute phase mediator IL-6 was
delayed in the samples from BD compared to STW. On the other hand, when using proteomics
of the wound fluid, the negative acute phase markers AHSG and A1I3 were more abundant in
STW. The neutrophil chemoattractants CXCL1, CXCL2 and CXCL3 were quantified with
either a higher or earlier response in the BD dialysates. This finding was supported by wound
fluid proteomics which revealed a higher abundance of neutrophil cytosolic proteins (NGP,
NCF2 and NCF4) as well as by the presence of neutrophil migration factors (ITGB2 and
S1009A). Moreover, neutrophil-released proteases (Cat-G, MMP8 and PR3) were enriched in
the wound fluids of the BD group. With regard to an identification of a variety of protease
inhibitors in both wound scenarios but with only one specific inhibitor for the BD group, a
more intense innate immune response can be assumed after the femur fracture compared to
the STW control group. This is supported by a higher abundance of fibrin and fibronectin con-
stituting of a provisional ECM composed of fibrin and fibronectin, which were higher abun-
dant in the STW group compared to the BD. Recently, non-healing wounds are mainly
thought to be linked to an imbalanced and persistent immune response that overwhelms the
tissue protective capabilities [19, 72, 77]. Hence, the monitoring of immune modulators, prote-
ases and their corresponding inhibitors could serve as markers for the wound and fracture
healing progress.
Future studies employing combined sampling should focus on the comparative monitoring
of healing and non-healing bone defects under different conditions that could reveal the molec-
ular background of the healing progress. Moreover, this technique could be used for assessing
the host response towards different bone graft or bone substitute materials. However, this sam-
pling approach is not limited to immune-related questions since proteins involved in several
biological processes, like sugar metabolism and cytoskeleton organization, could be identified.
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